Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 6.72%
As of Thursday, September 24, Foghorn Therapeutics Inc.’s FHTX share price has dipped by 6.72%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 5.78%
As of Wednesday, September 23, Foghorn Therapeutics Inc.’s FHTX share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Michael Rose
Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 5.28%
As of Tuesday, September 15, Foghorn Therapeutics Inc.’s FHTX share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 5.80%
As of Wednesday, September 02, Foghorn Therapeutics Inc.’s FHTX share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 10.02%
As of Wednesday, September 02, Foghorn Therapeutics Inc.’s FHTX share price has dipped by 10.02%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | FHTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $207.8 | $257.9 | 28% |
|
| Shares Out (Mil) | 70.6 | 54.3 | 55% |
|
| Institutional Ownership | 83.4% | 92.9% | 51% |
|
| Float (Mil) | 28.1 | 41.4 | 35% |
|
| Beta | 2.84 | 0.95 | 97% |
|
| Avg Daily Volume (000s) | 533 | 674 | 57% |
|
| Price Change (52-week) |
(28.7%) | 51.5% | 29% |
|
| Growth | FHTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 138.6% | 13.2% | 99% |
|
| Net Income (5yr) | (1.6%) | (10.1%) | 38% |
|
| EPS (5yr) | 28.3% | 15.8% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (42.8%) | (15.6%) | 10% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($0.230) | ($0.875) | ($1.091) | |
| Month Ago EPS | ($0.240) | ($0.870) | ($1.029) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.240) | ($0.990) | ($0.929) | |
| Year/Year Chg | 125.5% | (25.8%) | (48.3%) | |
| Financials | FHTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($65) | ($43) | 14% |
|
| EPS (TTM) | ($0.970) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($84) | ($32) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $2 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $40 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $295 | $174 | 29% |
|
| Valuation | FHTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.51 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FHTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (114.6%) | 68.9% | 2% |
|
| Net Margin | (175.8%) | (72.5%) | 5% |
|
| ROA | (30.1%) | (47.7%) | 17% |
|
| ROE | 81.9% | (54.9%) | 95% |
|
| Liabilities to Assets | 139.8% | 29.1% | 98% |
|
| F-Score | 3 | 3 | 18% |
|
Foghorn Therapeutics Inc. did not pass any screens on 9/25/2026.
